Hepatitis C overview
As a result of massive strides taken in recent years in the development and roll-out of direct acting antiviral treatments for hepatitis C it has become possible to plan the elimination of hepatitis C virus (HCV) worldwide. Numerous clinical trials have been published showing >95% effective cure in the majority of patients treated with these new therapies.
In response to this (and a similar situation with hepatitis B) The World Health Organisation (WHO) has developed guidance for the global elimination of the hepatitis B and C viruses by 2030; all WHO member states are signed up to this objective. Prof. Thomson is a member of the WHO hepatitis C screening, diagnosis and treatment guidelines committee.
The CVR is further contributing to the elimination plan by investigating the components of a protective immune response during early (acute) hepatitis C infection, this work will assist in:
- the development of vaccine candidates
- investigating the response to treatment in sub-Saharan Africa
- monitoring drug resistance in the UK